Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
1.21M
-
Shares change
-
-6.18K
-
Total reported value, excl. options
-
$3.78M
-
Value change
-
-$19.3K
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$3.13
Significant Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2022
22 filings reported holding GANX - Gain Therapeutics, Inc. - COM as of Q4 2022.
Gain Therapeutics, Inc. - COM (GANX) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.21M shares
.
Largest 10 shareholders include GREENLIGHT CAPITAL INC (547K shares), Telemetry Investments, L.L.C. (123K shares), CM Management, LLC (110K shares), GEODE CAPITAL MANAGEMENT, LLC (90.1K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (60K shares), PRELUDE CAPITAL MANAGEMENT, LLC (58.1K shares), Royal Bank of Canada (39K shares), RENAISSANCE TECHNOLOGIES LLC (33.2K shares), BlackRock Inc. (25K shares), and RAYMOND JAMES & ASSOCIATES (24K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.